Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.62 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SGK1 | O00141 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953501 | 1.00 | TTK (0.62) | TTKITKAURKBTRPA1SCN5A | |
| SCHEMBL4514654 | 0.87 | TTK (0.48) | TTKITKMAPK10RIPK1 | |
| SCHEMBL3709667 | 0.80 | TTK (0.61) | TTKITKAURKBTRPA1GSK3B | |
| SCHEMBL3709670 | 0.80 | TTK (0.61) | TTKITKAURKBTRPA1GSK3B | |
| SCHEMBL15304355 | 0.78 | ITK (0.46) | TTKITKCHEK1 | |
| SCHEMBL29955085 | 0.78 | ITK (0.46) | TTKITKCHEK1 | |
| SCHEMBL586433 | 0.77 | TTK (1.00) | TTKAURKBCHEK1 | |
| SCHEMBL586434 | 0.77 | TTK (1.00) | TTKAURKBCHEK1 | |
| SCHEMBL1799976 | 0.76 | PDPK1 (0.55) | TTKITKAURKBTRPA1SCN5A | |
| SCHEMBL3538242 | 0.76 | TTK (0.54) | TTKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| EP-2556071-B1 | KINASE INHIBITORS AND THEIR USE IN TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2016-08-17 | — | — | EP | disclosed |
| EP-2556071-B1 | KINASE INHIBITORS AND THEIR USE IN TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2016-08-17 | — | — | EP | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
| US-7105537-B2 | 2-substituted cyclic amines as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040229860-A1 | Novel 2-substituted cyclic amines as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
| WO-2004069793-A2 | NOVEL 2-SUBSTITUTED CYCLIC AMINES AS CALCIUM SENSING RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885ITK 412/4885AURKB 180/4885 |
| US-20040229860-A1 | Novel 2-substituted cyclic amines as calcium sensing receptor modulators | CASR, RYR1, CACNA1E | TTK 1926/4885ITK 3895/4885AURKB 1293/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885ITK 412/4885AURKB 180/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885ITK 412/4885AURKB 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.